Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) CAO Theodore Alan Huizenga sold 970 shares of the stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $37.15, for a total value of $36,035.50. Following the completion of the sale, the chief accounting officer now directly owns 23,777 shares of the company’s stock, valued at $883,315.55. The sale was disclosed in a filing with the SEC, which is available at this link.
Ultragenyx Pharmaceutical Price Performance
Shares of RARE opened at $38.79 on Thursday. The company has a market capitalization of $2.77 billion, a PE ratio of -3.79 and a beta of 0.87. Ultragenyx Pharmaceutical Inc. has a one year low of $33.36 and a one year high of $54.98. The company’s fifty day moving average price is $40.54 and its 200 day moving average price is $43.30.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($2.25) earnings per share for the quarter, missing the consensus estimate of ($2.11) by ($0.14). The business had revenue of $108.30 million for the quarter, compared to analyst estimates of $107.10 million. Ultragenyx Pharmaceutical had a negative return on equity of 220.54% and a negative net margin of 178.91%. Ultragenyx Pharmaceutical’s revenue for the quarter was up 21.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.26) EPS. Analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -8.65 earnings per share for the current year.
Analysts Set New Price Targets
Institutional Investors Weigh In On Ultragenyx Pharmaceutical
Several hedge funds and other institutional investors have recently modified their holdings of RARE. Vanguard Group Inc. grew its position in Ultragenyx Pharmaceutical by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 6,161,866 shares of the biopharmaceutical company’s stock worth $255,163,000 after purchasing an additional 27,722 shares during the last quarter. BlackRock Inc. lifted its position in shares of Ultragenyx Pharmaceutical by 4.0% in the 2nd quarter. BlackRock Inc. now owns 5,067,027 shares of the biopharmaceutical company’s stock worth $233,742,000 after acquiring an additional 193,671 shares during the period. RTW Investments LP grew its holdings in shares of Ultragenyx Pharmaceutical by 7.7% during the 1st quarter. RTW Investments LP now owns 4,270,996 shares of the biopharmaceutical company’s stock worth $171,267,000 after purchasing an additional 304,081 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Ultragenyx Pharmaceutical by 17.1% during the first quarter. Wellington Management Group LLP now owns 3,370,245 shares of the biopharmaceutical company’s stock valued at $244,747,000 after purchasing an additional 492,842 shares during the period. Finally, Avidity Partners Management LP raised its stake in shares of Ultragenyx Pharmaceutical by 45.7% in the fourth quarter. Avidity Partners Management LP now owns 2,990,000 shares of the biopharmaceutical company’s stock valued at $138,527,000 after purchasing an additional 938,400 shares in the last quarter. Institutional investors and hedge funds own 96.37% of the company’s stock.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
- Five stocks we like better than Ultragenyx Pharmaceutical
- Overbought Stocks Explained: Should You Trade Them?
- Battle Of The Digital Payment Titans: Block, PayPal, And Visa
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- These Quality Dividend Kings Grow their Dividends the Fastest
- The 3 Best Retail Stocks to Shop for in August
- 3 Growth Stocks to Buy in September
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.